# Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma

Source: https://onco.cc/trials/nct03172299/  
OnCo record `nct03172299` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ziv-aflibercept in Uveal melanoma, run by Centre Hospitalier Universitaire de Nice, completed.

## Summary

Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated with Proton Therapy for a Large Choroidal Melanoma is a phase 3 interventional study registered as NCT03172299 by Centre Hospitalier Universitaire de Nice, with 57 participants recorded, started 2017-06-08 and reaching its primary completion in 2025-01-31. Interventions recorded: Aflibercept Injection, False injection. Conditions recorded: Ocular Melanoma.

Linked to the drug Ziv-aflibercept because the registry names it among its interventions and Uveal melanoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03172299
- Phase: 3
- Setting: Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-Vascular Endothelial Growth Factor in Patients Treated with Proton Therapy for a Large Choroidal Melanoma
- Sponsor: Centre Hospitalier Universitaire de Nice
- Enrolled: 57

## Sources

- ClinicalTrials.gov NCT03172299: https://clinicaltrials.gov/study/NCT03172299

## Connected records

- cancers: [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- drugs: [Ziv-aflibercept](https://onco.cc/drugs/ziv-aflibercept/)

---
JSON: https://onco.cc/api/v1/entities/nct03172299.json